How Primary Care Physicians Can Approach the Use of GLP-1 Receptor Agonists for Weight Loss

February 7th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

August 30th 2023

Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction / image credit ©CLIPAREA_Custom Media/Shutterstock.com

January 27th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

June 30th 2023

GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

GLP-1 Mimetic Benefits Are Broad, Study Finds, But Risks Can't be Ignored / image credit Courtesy of Washington University School of Medicine

Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.

Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

Related Content

February 7th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

August 30th 2023

Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 27th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

June 30th 2023

GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.